+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 4
Age: 18Years +
All Genders
ID07434635

APPRAISE study on Atropine Eye Drops for Reducing Pain and Posterior Synechiae After Eye Surgery

Led by University of California, San Francisco · Updated on 2026-07-31

62

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating whether atropine eyedrops provide benefits after certain eye surgeries in patients with eye disorders. The study compares outcomes between patients who use atropine eyedrops following surgery and those who do not. This Phase 4 trial aims to better understand the effects of atropine on pain and other post-surgical eye conditions. Participants are randomly assigned to one of two groups one group will use atropine 1% eyedrops after surgery, while the other group will not receive atropine as part of their post-operative care. The study follows a parallel design with single masking, meaning participants know their group assignment but some study personnel do not. The treatment is given after vitrectomy surgery, and participants are monitored for one month. During the study, participants undergo assessments of pain using the Visual Analog Scale at one month. Researchers also evaluate inflammation in the eyes anterior chamber, cystoid macular edema via imaging, time to visual recovery, intraocular pressure, and posterior synechiae formation. Safety and treatment effects are monitored throughout the one-month follow-up period. The total participation duration includes screening, treatment, and outcome assessments over this month.

CONDITIONS

Brief Title

APPRAISE: Assessment of Pain and Posterior Synechiae Reduction With Atropine, an Investigation of Post-Surgical Eyes

Research Team

J

Jay Stewart, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here